Cargando…
Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study
BACKGROUND: We aimed to assess the cost effectiveness of intravitreal ranibizumab (Lucentis), aflibercept (Eylea) and bevacizumab (Avastin) for the treatment of macular oedema due to central retinal vein occlusion. METHODS: We calculated costs and quality-adjusted life-years from the UK National Hea...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8298346/ https://www.ncbi.nlm.nih.gov/pubmed/33900585 http://dx.doi.org/10.1007/s40273-021-01026-5 |
_version_ | 1783726041410306048 |
---|---|
author | Pennington, Becky Alshreef, Abualbishr Flight, Laura Metry, Andrew Poku, Edith Hykin, Philip Sivaprasad, Sobha Prevost, A. Toby Vasconcelos, Joana C. Murphy, Caroline Kelly, Joanna Yang, Yit Lotery, Andrew Williams, Michael Brazier, John |
author_facet | Pennington, Becky Alshreef, Abualbishr Flight, Laura Metry, Andrew Poku, Edith Hykin, Philip Sivaprasad, Sobha Prevost, A. Toby Vasconcelos, Joana C. Murphy, Caroline Kelly, Joanna Yang, Yit Lotery, Andrew Williams, Michael Brazier, John |
author_sort | Pennington, Becky |
collection | PubMed |
description | BACKGROUND: We aimed to assess the cost effectiveness of intravitreal ranibizumab (Lucentis), aflibercept (Eylea) and bevacizumab (Avastin) for the treatment of macular oedema due to central retinal vein occlusion. METHODS: We calculated costs and quality-adjusted life-years from the UK National Health Service and Personal Social Services perspective. We performed a within-trial analysis using the efficacy, safety, resource use and health utility data from a randomised controlled trial (LEAVO) over 100 weeks. We built a discrete event simulation to model long-term outcomes. We estimated utilities using the Visual-Functioning Questionnaire-Utility Index, EQ-5D and EQ-5D with an additional vision question. We used standard UK costs sources for 2018/19 and a cost of £28 per bevacizumab injection. We discounted costs and quality-adjusted life-years at 3.5% annually. RESULTS: Bevacizumab was the least costly intervention followed by ranibizumab and aflibercept in both the within-trial analysis (bevacizumab: £6292, ranibizumab: £13,014, aflibercept: £14,328) and long-term model (bevacizumab: £18,353, ranibizumab: £30,226, aflibercept: £35,026). Although LEAVO did not demonstrate bevacizumab to be non-inferior for the visual acuity primary outcome, the three interventions generated similar quality-adjusted life-years in both analyses. Bevacizumab was always the most cost-effective intervention at a threshold of £30,000 per quality-adjusted life-year, even using the list price of £243 per injection. CONCLUSIONS: Wider adoption of bevacizumab for the treatment of macular oedema due to central retinal vein occlusion could result in substantial savings to healthcare systems and deliver similar health-related quality of life. However, patients, funders and ophthalmologists should be fully aware that LEAVO could not demonstrate that bevacizumab is non-inferior to the licensed agents. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40273-021-01026-5. |
format | Online Article Text |
id | pubmed-8298346 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-82983462021-08-12 Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study Pennington, Becky Alshreef, Abualbishr Flight, Laura Metry, Andrew Poku, Edith Hykin, Philip Sivaprasad, Sobha Prevost, A. Toby Vasconcelos, Joana C. Murphy, Caroline Kelly, Joanna Yang, Yit Lotery, Andrew Williams, Michael Brazier, John Pharmacoeconomics Original Research Article BACKGROUND: We aimed to assess the cost effectiveness of intravitreal ranibizumab (Lucentis), aflibercept (Eylea) and bevacizumab (Avastin) for the treatment of macular oedema due to central retinal vein occlusion. METHODS: We calculated costs and quality-adjusted life-years from the UK National Health Service and Personal Social Services perspective. We performed a within-trial analysis using the efficacy, safety, resource use and health utility data from a randomised controlled trial (LEAVO) over 100 weeks. We built a discrete event simulation to model long-term outcomes. We estimated utilities using the Visual-Functioning Questionnaire-Utility Index, EQ-5D and EQ-5D with an additional vision question. We used standard UK costs sources for 2018/19 and a cost of £28 per bevacizumab injection. We discounted costs and quality-adjusted life-years at 3.5% annually. RESULTS: Bevacizumab was the least costly intervention followed by ranibizumab and aflibercept in both the within-trial analysis (bevacizumab: £6292, ranibizumab: £13,014, aflibercept: £14,328) and long-term model (bevacizumab: £18,353, ranibizumab: £30,226, aflibercept: £35,026). Although LEAVO did not demonstrate bevacizumab to be non-inferior for the visual acuity primary outcome, the three interventions generated similar quality-adjusted life-years in both analyses. Bevacizumab was always the most cost-effective intervention at a threshold of £30,000 per quality-adjusted life-year, even using the list price of £243 per injection. CONCLUSIONS: Wider adoption of bevacizumab for the treatment of macular oedema due to central retinal vein occlusion could result in substantial savings to healthcare systems and deliver similar health-related quality of life. However, patients, funders and ophthalmologists should be fully aware that LEAVO could not demonstrate that bevacizumab is non-inferior to the licensed agents. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40273-021-01026-5. Springer International Publishing 2021-04-26 2021 /pmc/articles/PMC8298346/ /pubmed/33900585 http://dx.doi.org/10.1007/s40273-021-01026-5 Text en © The Author(s) 2021, corrected publication 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Research Article Pennington, Becky Alshreef, Abualbishr Flight, Laura Metry, Andrew Poku, Edith Hykin, Philip Sivaprasad, Sobha Prevost, A. Toby Vasconcelos, Joana C. Murphy, Caroline Kelly, Joanna Yang, Yit Lotery, Andrew Williams, Michael Brazier, John Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study |
title | Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study |
title_full | Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study |
title_fullStr | Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study |
title_full_unstemmed | Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study |
title_short | Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study |
title_sort | cost effectiveness of ranibizumab vs aflibercept vs bevacizumab for the treatment of macular oedema due to central retinal vein occlusion: the leavo study |
topic | Original Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8298346/ https://www.ncbi.nlm.nih.gov/pubmed/33900585 http://dx.doi.org/10.1007/s40273-021-01026-5 |
work_keys_str_mv | AT penningtonbecky costeffectivenessofranibizumabvsafliberceptvsbevacizumabforthetreatmentofmacularoedemaduetocentralretinalveinocclusiontheleavostudy AT alshreefabualbishr costeffectivenessofranibizumabvsafliberceptvsbevacizumabforthetreatmentofmacularoedemaduetocentralretinalveinocclusiontheleavostudy AT flightlaura costeffectivenessofranibizumabvsafliberceptvsbevacizumabforthetreatmentofmacularoedemaduetocentralretinalveinocclusiontheleavostudy AT metryandrew costeffectivenessofranibizumabvsafliberceptvsbevacizumabforthetreatmentofmacularoedemaduetocentralretinalveinocclusiontheleavostudy AT pokuedith costeffectivenessofranibizumabvsafliberceptvsbevacizumabforthetreatmentofmacularoedemaduetocentralretinalveinocclusiontheleavostudy AT hykinphilip costeffectivenessofranibizumabvsafliberceptvsbevacizumabforthetreatmentofmacularoedemaduetocentralretinalveinocclusiontheleavostudy AT sivaprasadsobha costeffectivenessofranibizumabvsafliberceptvsbevacizumabforthetreatmentofmacularoedemaduetocentralretinalveinocclusiontheleavostudy AT prevostatoby costeffectivenessofranibizumabvsafliberceptvsbevacizumabforthetreatmentofmacularoedemaduetocentralretinalveinocclusiontheleavostudy AT vasconcelosjoanac costeffectivenessofranibizumabvsafliberceptvsbevacizumabforthetreatmentofmacularoedemaduetocentralretinalveinocclusiontheleavostudy AT murphycaroline costeffectivenessofranibizumabvsafliberceptvsbevacizumabforthetreatmentofmacularoedemaduetocentralretinalveinocclusiontheleavostudy AT kellyjoanna costeffectivenessofranibizumabvsafliberceptvsbevacizumabforthetreatmentofmacularoedemaduetocentralretinalveinocclusiontheleavostudy AT yangyit costeffectivenessofranibizumabvsafliberceptvsbevacizumabforthetreatmentofmacularoedemaduetocentralretinalveinocclusiontheleavostudy AT loteryandrew costeffectivenessofranibizumabvsafliberceptvsbevacizumabforthetreatmentofmacularoedemaduetocentralretinalveinocclusiontheleavostudy AT williamsmichael costeffectivenessofranibizumabvsafliberceptvsbevacizumabforthetreatmentofmacularoedemaduetocentralretinalveinocclusiontheleavostudy AT brazierjohn costeffectivenessofranibizumabvsafliberceptvsbevacizumabforthetreatmentofmacularoedemaduetocentralretinalveinocclusiontheleavostudy |